This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brown, L. Articles by Burstow, D. Search for Related Content PubMed Articles by Brown, L. Articles by Burstow, D. Social Bookmarking                         What's this?

Reversal of cardiovascular remodelling with candesartan

Department of Physiology and Pharmacology, The University of Queensland, brown{at}plpk.uq.edu.au

Andrew Fenning

Department of Physiology and Pharmacology, The University of Queensland

Annie Shek

Department of Physiology and Pharmacology, The University of Queensland

Darryl Burstow

The Prince Charles Hospital, Brisbane, Australia

Cardiovascular remodelling, defined as ventricular and vascular hypertrophy together with fibrosis, characterises hypertension following inhibition of the production of the endogenous vasodilator, nitric oxide (NO). This study has determined whether the cardiovascular remodelling following chronic NO synthase inhibition can be reversed by administration of the selective angiotensin II AT₁-receptor antagonist, candesartan. Male Wistar rats were treated with L-nitroarginine methyl ester (L-NAME, 400 mg/l in drinking water) for eight weeks and with candesartan cilexetil (2 mg/kg/day by oral gavage) for the last four weeks. L-NAME-treated rats became hypertensive with systolic blood pressure increasing from 110±4 mmHg (control) to 170±10 mmHg. Rats developed left ventricular hypertrophy (control 1.70±0.06; L-NAME 2.10±0.04 mg/kg body wt) with markedly increased deposition of perivascular and interstitial collagen. Candesartan returned blood pressure, left ventricular weights and collagen deposition to control values. Echocardiographic assessment showed concentric hypertrophy with an increased fractional shortening; this was reversed by candesartan treatment. Heart failure was not evident. In the isolated Langendorff heart, diastolic stiffness increased in L-NAME-treated rats while the rate of increase in pressure (+dP/dt) increased after eight weeks only; candesartan reduced collagen deposition and normalised +dP/dt. In isolated left ventricular papillary muscles, the potency (negative log EC₅₀) of noradrenaline as a positive inotropic compound was unchanged, (control 6.56±0.14); maximal increase in force before ectopic beats was reduced from 5.0±0.4 mN to 2.0±0.2 mN. Noradrenaline potency as a vasoconstrictor in thoracic aortic rings was unchanged, but maximal contraction was markedly reduced from 25.2±2.0 mN to 3.0±0.3 mN; this was partially reversed by candesartan treatment. Thus, chronic inhibition of NO production with L-NAME induces hypertension, hypertrophy and fibrosis with increased toxicity and significant decreases in vascular responses to noradrenaline. These changes were at least partially reversible by treatment with candesartan, implying a significant role of AT₁-receptors in L-NAME-induced cardiovascular changes.

Key Words: cardiac remodelling • hypertrophy fibrosis • AT1-receptors

References

• Vila-Petroff MG, Lakatta EG Nitric oxide: a multifaceted modulator of cardiac contractility. Asia Pacific Heart J 1998;7:38-42.[CrossRef]
• MacCarthy PA, Shah AM The role of nitric oxide in the regulation of myocardial relaxation and diastolic function. Asia Pacific Heart J 1998;7:29-37.[CrossRef]
• Takemoto M., Egashira K., Tomita H. et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade. Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997;30:1621-7.[Abstract/Free Full Text]
• Bartunek J.,Weinberg EO,Tajima M. et al. Chronic NG-nitro-L-arginine methyl ester-induced hypertension. Novel molecular adaptation to systolic load in absence of hypertrophy. Circulation 2000;101:423-9.[Abstract/Free Full Text]
• Katz A. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990;22:739-47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fernández-Alfonso MS, González C. Nitric oxide and the renin-angiotensin system. Is there a physiological interplay between the systems? J Hypertens 1999;17:1355-61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Katoh M., Egashira K., Usui M. et al. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res 1998;83:743-51.[Abstract/Free Full Text]
• Usui M., Egashira K.,Timita H. et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000;101:305-10.[Abstract/Free Full Text]
• Weber KT, Brilla CG, Janicki JS Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27:341-8.[Free Full Text]
• Brown L., Duce B., Miric G., Sernia C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 1999; 10: S143-S148.[Web of Science][Medline] [Order article via Infotrieve]
• Brown L., Sernia C., Newling R., Fletcher P. Comparison of inotropic and chronotropic responses in rat isolated atria and ventricles. Clin Exp Pharmacol Physiol 1991;18:753-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Brown L., Cragoe EJ Jr, Abel KC, Manley SW, Bourke JR Amiloride analogues induce responses in isolated rat cardiovascular tissues by inhibition of Na+/Ca2+ exchange. Naunyn-Schmiedeberg's Arch Pharmacol 1991;344:220-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mirsky I., Parmley WW Assessment of passive elastic stiffness for isolated heart muscle and the intact heart. Circ Res 1973;33:233-43.[Abstract/Free Full Text]
• Loscalzo J., Welch G. Nitric oxide and its role in the cardiovascular system. Progr Cardiovasc Dis 1995;38:87-104.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 1998;39:89-105.[Free Full Text]
• Bernátová I., Pecháñová O., Pelouch V., Simko F. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol 2000;32:177-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Marchant C., Brown L., Sernia C. Renin-angiotensin system in thyroid dysfunction in rats. J Cardiovasc Pharmacol 1993;22:449-55.[Web of Science][Medline] [Order article via Infotrieve]
• Litwin SE, Katz SE, Weinberg EO, Lorell BH, Aurigemma GP, Douglas PS Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 1995;91:2642-54.[Abstract/Free Full Text]
• Yoshiyama M., Takeuchi K., Omura T. et al. Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension 1999;33:961-8.[Abstract/Free Full Text]
• Norton GR, Tsotetsi J., Trifunovic B., Hartford C., Candy GP, Woodiwiss AJ Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 1997;96:1991-8.[Abstract/Free Full Text]
• Brown L., Sernia C., Newling R., Fletcher P. Cardiac responses after norepinephrine-induced ventricular hypertrophy in rats. J Cardiovasc Pharmacol 1992;20:316-23.[Web of Science][Medline] [Order article via Infotrieve]
• Pecháñová O., Bernátová I., Pelouch V., Simko F. Protein remodelling of the heart in NO deficient hypertension: the effect of captopril. J Mol Cell Cardiol 1997;29:3365-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pollock DM, Polakowski JS, Opgenorth TJ, Pollock JS Role of endothelin ETA receptors in the hypertension produced by 4-day L-nitroarginine methyl ester and cyclosporine treatment. Eur J Pharmacol 1998; 346:43-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 1 suppl, S141-S147 (2001)
DOI: 10.1177/14703203010020012501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brown, L. Articles by Burstow, D. Search for Related Content PubMed Articles by Brown, L. Articles by Burstow, D. Social Bookmarking                         What's this?